Date: 2016-12-12
Type of information: Nomination
Compound:
Company: Alexion Pharmaceuticals (USA - CT)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On December 12, 2016, Alexion Pharmaceuticals announced that it has named David Brennan as Interim Chief Executive Officer, effective immediately. Mr. Brennan is the former Chief Executive Officer and Executive Director of AstraZeneca and has been a member of the Alexion Board of Directors since July 2014 . Mr. Brennan succeeds David Hallal who has resigned for personal reasons, effective immediately. Mr. Hallal has also resigned from the Board. Spencer Stuart has been engaged to commence the search for a permanent CEO.
- In addition, the Board announced that David J. Anderson , the former Senior Vice President and Chief Financial Officer of Honeywell for 11 years, has joined the Company as Chief Financial Officer, effective immediately. Mr. Anderson succeeds Vikas Sinha , who has left Alexion to pursue other opportunities.
Financial terms:
Latest news:
Is general: Yes
